What the business is, and whether it's a good one at a fair price.
Designs, manufactures and integrates process equipment, containment systems, cleanroom partitions and utilities for pharmaceutical manufacturing facilities in emerging markets, with in-house compliance to WHO, EU-GMP, USFDA and UKMHRA standards. FY26 consolidated revenue was ₹410.77 crore, with the largest shares from Rest of the World (31.6%), UAE (27.9%) and Saudi Arabia (18.2%); India contributed 10.0%, Kenya 9.6%, with smaller contributions from Egypt (1.4%) and Algeria (1.4%). The order book stood at over ₹900 crore, giving 18-24 months of execution visibility, alongside a hot-lead pipeline of ~$200 million USD. A ₹230 crore equity infusion lifted cash and bank balances 5x to ₹208.57 crore and cut debt from ₹54 crore to ₹42 crore, leaving the balance sheet net cash. The cost structure is dominated by other operating expenses at 21.9% of revenue and employee costs at 10.5%, with raw material cost flagged as a +33% headwind and execution cost a +43% headwind during the year. The business is project-based, dependent on capex cycles of pharma customers across MENA, Africa and India.
Measured from the filed financials, judged against its Medical Equipment & Supplies peers · as of FY26 — not investment advice
How has the market priced it — with filings on the timeline?
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
How does it stack up on valuation, returns and growth?
Loading peers…
Quarterly & annual P&L, balance sheet, cash flow, ratios and segments.
Loading financials…
Who owns it — and is the promoter stake clean?
Loading shareholding…
Sign up to see the full company file
Governance, sustainability, compliance, earnings calls, presentations, events, reactions and the full filings feed — free with an account.
Answered from FABTECH TECHNOLOGIES LTD's filed financials and exchange disclosures
FABTECH TECHNOLOGIES LTD is a Healthcare Equipment & Supplies company listed on NSE and BSE, trading under the symbol FABTECH.
Yes. Over the trailing twelve months FABTECH TECHNOLOGIES LTD reported a net profit of ₹49 Cr on revenue of ₹418 Cr.
Not in the latest reported year — FABTECH TECHNOLOGIES LTD's dividend payout for FY26 was nil.
Effectively yes. It holds ₹44 Cr more cash than debt. Debt stands at 0.10× equity.
On trailing P/E, FABTECH TECHNOLOGIES LTD ranks 3 of 17 in Medical Equipment & Supplies — cheaper than 88% of them, against an industry median of 20.0×. This is a position, not a valuation judgement.
On a typical session FABTECH TECHNOLOGIES LTD moves 1.13% — that is the median absolute close-to-close move across its last 230 trading days. Announcement days are routinely larger.
Every NSE and BSE filing by FABTECH TECHNOLOGIES LTD appears on this page, AI-summarised, alongside the price reaction that followed it. Follow the company to get each new filing on WhatsApp within minutes.
Figures are as last reported and may lag the latest filing. Not investment advice.
